JP7541538B2 - 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体 - Google Patents

癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体 Download PDF

Info

Publication number
JP7541538B2
JP7541538B2 JP2021572409A JP2021572409A JP7541538B2 JP 7541538 B2 JP7541538 B2 JP 7541538B2 JP 2021572409 A JP2021572409 A JP 2021572409A JP 2021572409 A JP2021572409 A JP 2021572409A JP 7541538 B2 JP7541538 B2 JP 7541538B2
Authority
JP
Japan
Prior art keywords
equiv
methyl
mmol
mixture
μmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021572409A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020247475A5 (https=
JP2022535577A (ja
JP2022535577A5 (https=
Inventor
マルクス，マシュー，アーノルド
ケチャム，ジョン，マイケル
バーンズ，アーロン，クレイグ
Original Assignee
ミラティ セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミラティ セラピューティクス，インク． filed Critical ミラティ セラピューティクス，インク．
Publication of JP2022535577A publication Critical patent/JP2022535577A/ja
Publication of JPWO2020247475A5 publication Critical patent/JPWO2020247475A5/ja
Publication of JP2022535577A5 publication Critical patent/JP2022535577A5/ja
Application granted granted Critical
Publication of JP7541538B2 publication Critical patent/JP7541538B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021572409A 2019-06-05 2020-06-03 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体 Active JP7541538B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962857515P 2019-06-05 2019-06-05
US62/857,515 2019-06-05
PCT/US2020/035891 WO2020247475A1 (en) 2019-06-05 2020-06-03 Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer

Publications (4)

Publication Number Publication Date
JP2022535577A JP2022535577A (ja) 2022-08-09
JPWO2020247475A5 JPWO2020247475A5 (https=) 2023-05-08
JP2022535577A5 JP2022535577A5 (https=) 2023-05-08
JP7541538B2 true JP7541538B2 (ja) 2024-08-28

Family

ID=71842807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572409A Active JP7541538B2 (ja) 2019-06-05 2020-06-03 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体

Country Status (9)

Country Link
US (2) US12252493B2 (https=)
EP (1) EP3980422A1 (https=)
JP (1) JP7541538B2 (https=)
KR (1) KR20220027933A (https=)
CN (1) CN114269748A (https=)
AU (1) AU2020288563A1 (https=)
CA (1) CA3142711A1 (https=)
IL (1) IL288529A (https=)
WO (1) WO2020247475A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
US12252493B2 (en) 2019-06-05 2025-03-18 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
CN114907385A (zh) * 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023016511A1 (zh) * 2021-08-11 2023-02-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023049723A1 (en) * 2021-09-24 2023-03-30 Oric Pharmaceuticals, Inc. Prc2 inhibitors for use in treating blood disorders
EP4404932A4 (en) * 2021-09-24 2025-07-23 Oric Pharmaceuticals Inc PRC2 INHIBITORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS
EP4630004A1 (en) * 2022-12-05 2025-10-15 Oric Pharmaceuticals, Inc. Treatment of prostate cancer having androgen receptor variants
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma
IL326327A (en) * 2023-08-04 2026-04-01 Oric Pharmaceuticals Inc Prostate cancer treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017221100A1 (en) 2016-06-20 2017-12-28 Novartis Ag Imidazopyrimidine compounds useful for the treatment of cancer
JP2018500342A (ja) 2014-12-23 2018-01-11 ノバルティス アーゲー トリアゾロピリミジン化合物およびその使用
WO2019062435A1 (zh) 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2010021381A1 (ja) 2008-08-22 2010-02-25 武田薬品工業株式会社 縮合複素環誘導体およびその用途
UA110112C2 (uk) 2010-05-07 2015-11-25 Глаксосмітклайн Ллс Індоли
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
ES2951688T3 (es) 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
WO2013063417A1 (en) 2011-10-27 2013-05-02 Memorial Sloan-Kettering Cancer Center Methyltransferase inhibitors for treating cancer
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
SG10201912111TA (en) 2012-04-13 2020-02-27 Epizyme Inc Combination therapy for treating cancer
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
US9105490B2 (en) 2012-09-27 2015-08-11 Taiwan Semiconductor Manufacturing Company, Ltd. Contact structure of semiconductor device
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
MX2015004721A (es) 2012-10-15 2016-01-25 Epizyme Inc Compuestos de benceno sustituidos.
KR20230156450A (ko) 2012-10-15 2023-11-14 에피자임, 인코포레이티드 암을 치료하는 방법
EP2931707A4 (en) 2012-12-13 2016-07-20 Glaxosmithkline Llc AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS
AU2013361060B2 (en) 2012-12-21 2018-04-19 Epizyme, Inc. 1,4-pyridone compounds
CA2894222A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
SI2953941T1 (sl) 2013-02-11 2017-08-31 Constellation Pharmaceuticals, Inc. Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014151142A1 (en) 2013-03-15 2014-09-25 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
EP2991980B1 (en) 2013-04-30 2019-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
BR112015030515A2 (pt) 2013-06-06 2017-07-25 Glaxosmithkline Ip No 2 Ltd intensificadores de inibidores de homólogo 2 de zeste
KR20160030221A (ko) 2013-07-10 2016-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015077194A1 (en) 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015128837A1 (en) 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
CN106255693A (zh) 2014-03-07 2016-12-21 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2的抑制剂
SI3121175T1 (sl) 2014-03-17 2020-07-31 Daiichi Sankyo Company, Limited Derivati 1,3-benzodioksola kot EZH1 in/ali EZH2 inhibitorji
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
EP3157915B1 (en) 2014-06-17 2019-02-27 Pfizer Inc Substituted dihydroisoquinolinone compounds
CN107148419A (zh) 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
EP3215160A4 (en) 2014-11-06 2018-08-08 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
EP3885343A1 (en) 2014-11-06 2021-09-29 Dana-Farber Cancer Institute, Inc. Indole compounds as ezh2 inhibitors and uses thereof
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
IL236420A (en) 2014-12-23 2016-06-30 Ron Schneider Methods and systems for producing an enlarged 3D image
WO2016123387A1 (en) 2015-01-30 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
WO2016130396A1 (en) 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
RS59763B1 (sr) 2015-11-19 2020-02-28 Jiangsu Hengrui Medicine Co Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini
CN108697716A (zh) 2015-12-07 2018-10-23 Epizyme股份有限公司 Ezh2抑制剂及其使用方法
WO2017174023A1 (zh) 2016-04-08 2017-10-12 南京明德新药研发股份有限公司 作为ezh2抑制剂的联苯化合物
AU2017252460B2 (en) 2016-04-22 2021-11-18 Dana-Farber Cancer Institute, Inc. EZH2 inhibitors and uses thereof
CA3023157A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US9957274B2 (en) 2016-05-06 2018-05-01 Abbvie Inc. Indane inhibitors of EED and methods of their use
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
WO2017218953A1 (en) 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CN109942556A (zh) 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
CN110156787B (zh) 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
US12421228B2 (en) 2019-04-22 2025-09-23 Mirati Therapeutics, Inc. Naphthyridine derivatives as PRC2 inhibitors
US12252493B2 (en) 2019-06-05 2025-03-18 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500342A (ja) 2014-12-23 2018-01-11 ノバルティス アーゲー トリアゾロピリミジン化合物およびその使用
WO2017221100A1 (en) 2016-06-20 2017-12-28 Novartis Ag Imidazopyrimidine compounds useful for the treatment of cancer
WO2019062435A1 (zh) 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病

Also Published As

Publication number Publication date
US12252493B2 (en) 2025-03-18
WO2020247475A1 (en) 2020-12-10
CA3142711A1 (en) 2020-12-10
IL288529A (en) 2022-01-01
US20220274990A1 (en) 2022-09-01
JP2022535577A (ja) 2022-08-09
US20250179082A1 (en) 2025-06-05
CN114269748A (zh) 2022-04-01
AU2020288563A1 (en) 2022-01-06
KR20220027933A (ko) 2022-03-08
EP3980422A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
JP7541538B2 (ja) 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体
JP7495555B2 (ja) Ｐｒｃ２阻害剤
JP7624404B2 (ja) Ｐｒｃ２阻害剤としてのナフチリジン誘導体
WO2023049724A1 (en) Prc2 inhibitors for use in treating blood disorders
HK40077182B (en) Prc2 inhibitors
HK40077182A (en) Prc2 inhibitors
HK40039589A (en) Prc2 inhibitors
HK40039589B (en) Prc2 inhibitors
EA043605B1 (ru) Ингибиторы prc2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240724

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240816

R150 Certificate of patent or registration of utility model

Ref document number: 7541538

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350